Last reviewed · How we verify

Hangzhou ACEA Pharmaceutical Research Co., Ltd. — Portfolio Competitive Intelligence Brief

Hangzhou ACEA Pharmaceutical Research Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Abivertinib Maleate Capsules Abivertinib Maleate Capsules phase 3 EGFR tyrosine kinase inhibitor EGFR (Epidermal Growth Factor Receptor) Oncology
Placebo Gefitinib Tablets Placebo Gefitinib Tablets phase 3 EGFR tyrosine kinase inhibitor EGFR Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. Beijing InnoCare Pharma Tech Co., Ltd. · 1 shared drug class
  3. Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
  4. Genentech, Inc. · 1 shared drug class
  5. Grupo de Investigación Clínica en Oncología Radioterapia · 1 shared drug class
  6. Hoffmann-La Roche · 1 shared drug class
  7. Millennium Pharmaceuticals, Inc. · 1 shared drug class
  8. Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hangzhou ACEA Pharmaceutical Research Co., Ltd.:

Cite this brief

Drug Landscape (2026). Hangzhou ACEA Pharmaceutical Research Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hangzhou-acea-pharmaceutical-research-co-ltd. Accessed 2026-05-17.

Related